1	2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Recent	_	_	JJ	_	_	_	_	_
2	Progress	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	Antiprotozoan	_	_	NNP	_	_	_	_	_
5	Agents	_	_	NNPS	_	_	_	_	_


1	2.1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Anti-Giardiasis	_	_	NNP	_	_	_	_	_


1	Giardiasis	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	caused	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	protozoan	_	_	NN	_	_	_	_	_
7	parasite	_	_	NN	_	_	_	_	_
8	G.	_	_	NN	_	_	_	_	_
9	intestinalis	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	also	_	_	RB	_	_	_	_	_
12	known	_	_	VBN	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	G.	_	_	FW	_	_	_	_	_
15	lamblia	_	_	FW	_	_	_	_	_
16	or	_	_	CC	_	_	_	_	_
17	G.	_	_	NNP	_	_	_	_	_
18	duodenalis	_	_	NNP	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	known	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	common	_	_	JJ	_	_	_	_	_
8	name	_	_	NN	_	_	_	_	_
9	“	_	_	``	_	_	_	_	_
10	beaver	_	_	NN	_	_	_	_	_
11	fever	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	”	_	_	''	_	_	_	_	_
14	because	_	_	IN	_	_	_	_	_
15	this	_	_	DT	_	_	_	_	_
16	infection	_	_	NN	_	_	_	_	_
17	was	_	_	VBD	_	_	_	_	_
18	reported	_	_	VBN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	campers	_	_	NNS	_	_	_	_	_
21	who	_	_	WP	_	_	_	_	_
22	drank	_	_	VBD	_	_	_	_	_
23	contaminated	_	_	VBN	_	_	_	_	_
24	water	_	_	NN	_	_	_	_	_
25	that	_	_	WDT	_	_	_	_	_
26	was	_	_	VBD	_	_	_	_	_
27	inhabited	_	_	VBN	_	_	_	_	_
28	by	_	_	IN	_	_	_	_	_
29	beavers	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Giardiasis	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	most	_	_	RBS	_	_	_	_	_
5	common	_	_	JJ	_	_	_	_	_
6	protozoan	_	_	NN	_	_	_	_	_
7	infection	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	human	_	_	JJ	_	_	_	_	_
10	beings	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	it	_	_	PRP	_	_	_	_	_
14	occurs	_	_	VBZ	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	both	_	_	CC	_	_	_	_	_
17	developing	_	_	VBG	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	industrialized	_	_	VBN	_	_	_	_	_
20	countries	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Its	_	_	PRP$	_	_	_	_	_
2	global	_	_	JJ	_	_	_	_	_
3	incidence	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	believed	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	range	_	_	VB	_	_	_	_	_
8	between	_	_	IN	_	_	_	_	_
9	20	_	_	CD	_	_	_	_	_
10	%	_	_	NN	_	_	_	_	_
11	–	_	_	TO	_	_	_	_	_
12	60	_	_	CD	_	_	_	_	_
13	%	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	2	_	_	CD	_	_	_	_	_
17	%	_	_	NN	_	_	_	_	_
18	–	_	_	:	_	_	_	_	_
19	7	_	_	CD	_	_	_	_	_
20	%	_	_	NN	_	_	_	_	_
21	incidence	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	industrialized	_	_	VBN	_	_	_	_	_
24	nations	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Giardia	_	_	NNP	_	_	_	_	_
2	intestinalis	_	_	NN	_	_	_	_	_


1	was	_	_	VBD	_	_	_	_	_
2	first	_	_	RB	_	_	_	_	_
3	described	_	_	VBN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	1681	_	_	CD	_	_	_	_	_
6	after	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	Dutch	_	_	JJ	_	_	_	_	_
9	microscopist	_	_	NN	_	_	_	_	_
10	Antonie	_	_	NNP	_	_	_	_	_
11	van	_	_	NNP	_	_	_	_	_
12	Leeuwenhoek	_	_	NNP	_	_	_	_	_
13	observed	_	_	VBD	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	protozoan	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	his	_	_	PRP$	_	_	_	_	_
18	own	_	_	JJ	_	_	_	_	_
19	diarrheic	_	_	JJ	_	_	_	_	_
20	stools	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	disease	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	often	_	_	RB	_	_	_	_	_
5	prevalent	_	_	JJ	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	poor	_	_	JJ	_	_	_	_	_
8	countries	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	communities	_	_	NNS	_	_	_	_	_
11	that	_	_	WDT	_	_	_	_	_
12	have	_	_	VBP	_	_	_	_	_
13	untreated	_	_	JJ	_	_	_	_	_
14	water	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	inadequate	_	_	JJ	_	_	_	_	_
17	sanitation	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	poor	_	_	JJ	_	_	_	_	_
21	dietary	_	_	JJ	_	_	_	_	_
22	status	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	infection	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	caused	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	fecal	_	_	JJ	_	_	_	_	_
7	–	_	_	:	_	_	_	_	_
8	oral	_	_	JJ	_	_	_	_	_
9	transmission	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	initiated	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	ingestion	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	infectious	_	_	JJ	_	_	_	_	_
17	cysts	_	_	NNS	_	_	_	_	_
18	from	_	_	IN	_	_	_	_	_
19	contaminated	_	_	VBN	_	_	_	_	_
20	water	_	_	NN	_	_	_	_	_
21	or	_	_	CC	_	_	_	_	_
22	through	_	_	IN	_	_	_	_	_
23	person-to-person	_	_	JJ	_	_	_	_	_
24	contact	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	After	_	_	IN	_	_	_	_	_
2	excystation	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	flagellated	_	_	JJ	_	_	_	_	_
5	trophozoites	_	_	NNS	_	_	_	_	_
6	colonize	_	_	VBP	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	upper	_	_	JJ	_	_	_	_	_
9	small	_	_	JJ	_	_	_	_	_
10	intestine	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	where	_	_	WRB	_	_	_	_	_
13	they	_	_	PRP	_	_	_	_	_
14	attach	_	_	VBP	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	epithelial	_	_	JJ	_	_	_	_	_
18	lining	_	_	NN	_	_	_	_	_
19	but	_	_	CC	_	_	_	_	_
20	do	_	_	VBP	_	_	_	_	_
21	not	_	_	RB	_	_	_	_	_
22	invade	_	_	VB	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	mucosa	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	duration	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	Giardia	_	_	NN	_	_	_	_	_
5	infection	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	variable	_	_	JJ	_	_	_	_	_
8	;	_	_	:	_	_	_	_	_
9	however	_	_	RB	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	chronic	_	_	JJ	_	_	_	_	_
12	infection	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	reinfection	_	_	NN	_	_	_	_	_
15	commonly	_	_	RB	_	_	_	_	_
16	occur	_	_	VBP	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Approximately	_	_	RB	_	_	_	_	_
2	50	_	_	CD	_	_	_	_	_
3	%	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	symptoms	_	_	NNS	_	_	_	_	_
7	classically	_	_	RB	_	_	_	_	_
8	associated	_	_	VBN	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	giardiasis	_	_	NN	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	asymptomatic	_	_	JJ	_	_	_	_	_
13	including	_	_	VBG	_	_	_	_	_
14	diarrhea	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	abdominal	_	_	JJ	_	_	_	_	_
17	pain	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	nausea	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	vomiting	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	anorexia	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	infected	_	_	VBN	_	_	_	_	_
4	individuals	_	_	NNS	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	also	_	_	RB	_	_	_	_	_
7	develop	_	_	VB	_	_	_	_	_
8	extraintestinal	_	_	JJ	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	postinfectious	_	_	JJ	_	_	_	_	_
11	complications	_	_	NNS	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Chronic	_	_	JJ	_	_	_	_	_
2	extraintestinal	_	_	JJ	_	_	_	_	_
3	sequelae	_	_	NN	_	_	_	_	_
4	may	_	_	MD	_	_	_	_	_
5	affect	_	_	VB	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	joints	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	skin	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	eyes	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	central	_	_	JJ	_	_	_	_	_
15	nervous	_	_	JJ	_	_	_	_	_
16	system	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	but	_	_	CC	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	underlying	_	_	VBG	_	_	_	_	_
21	mechanisms	_	_	NNS	_	_	_	_	_
22	are	_	_	VBP	_	_	_	_	_
23	unknown	_	_	JJ	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	According	_	_	VBG	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	research	_	_	NN	_	_	_	_	_
4	data	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	Giardia	_	_	NNP	_	_	_	_	_
7	has	_	_	VBZ	_	_	_	_	_
8	eight	_	_	CD	_	_	_	_	_
9	distinct	_	_	JJ	_	_	_	_	_
10	genetic	_	_	JJ	_	_	_	_	_
11	assemblages	_	_	NNS	_	_	_	_	_
12	labelled	_	_	VBN	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	assemblage	_	_	NN	_	_	_	_	_
15	“	_	_	``	_	_	_	_	_
16	A	_	_	NN	_	_	_	_	_
17	”	_	_	''	_	_	_	_	_
18	through	_	_	IN	_	_	_	_	_
19	“	_	_	``	_	_	_	_	_
20	H	_	_	NN	_	_	_	_	_
21	”	_	_	''	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	assemblages	_	_	NNS	_	_	_	_	_
25	“	_	_	``	_	_	_	_	_
26	A	_	_	DT	_	_	_	_	_
27	”	_	_	''	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	“	_	_	``	_	_	_	_	_
30	B	_	_	NN	_	_	_	_	_
31	”	_	_	''	_	_	_	_	_
32	are	_	_	VBP	_	_	_	_	_
33	responsible	_	_	JJ	_	_	_	_	_
34	for	_	_	IN	_	_	_	_	_
35	infection	_	_	NN	_	_	_	_	_
36	in	_	_	IN	_	_	_	_	_
37	humans	_	_	NNS	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Three	_	_	CD	_	_	_	_	_
2	classes	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	drugs	_	_	NNS	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	currently	_	_	RB	_	_	_	_	_
7	used	_	_	VBN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	treatment	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	giardiasis	_	_	NN	_	_	_	_	_
13	:	_	_	:	_	_	_	_	_
14	metronidazole	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	mepacrine	_	_	NN	_	_	_	_	_
17	analogs	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	nitrofurans	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	such	_	_	JJ	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	furazolidone	_	_	NN	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	1	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Metronidazole	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	most	_	_	RBS	_	_	_	_	_
5	widely	_	_	RB	_	_	_	_	_
6	used	_	_	VBN	_	_	_	_	_
7	drug	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	treatment	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	giardiasis	_	_	NN	_	_	_	_	_
13	globally	_	_	RB	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	it	_	_	PRP	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	generally	_	_	RB	_	_	_	_	_
18	effective	_	_	JJ	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	well-tolerated	_	_	JJ	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	United	_	_	NNP	_	_	_	_	_
5	States	_	_	NNPS	_	_	_	_	_
6	Food	_	_	NNP	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	Drug	_	_	NNP	_	_	_	_	_
9	Administration	_	_	NNP	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	FDA	_	_	NNP	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	has	_	_	VBZ	_	_	_	_	_
14	not	_	_	RB	_	_	_	_	_
15	yet	_	_	RB	_	_	_	_	_
16	approved	_	_	VBN	_	_	_	_	_
17	this	_	_	DT	_	_	_	_	_
18	drug	_	_	NN	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	treatment	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	Giardia	_	_	NN	_	_	_	_	_
24	infection	_	_	NN	_	_	_	_	_
25	because	_	_	IN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	its	_	_	PRP$	_	_	_	_	_
28	toxicity	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	major	_	_	JJ	_	_	_	_	_
31	side	_	_	NN	_	_	_	_	_
32	effects	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	such	_	_	JJ	_	_	_	_	_
35	as	_	_	IN	_	_	_	_	_
36	seizures	_	_	NNS	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	ataxia	_	_	NN	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	peripheral	_	_	JJ	_	_	_	_	_
41	neuropathy	_	_	NN	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	transient	_	_	JJ	_	_	_	_	_
44	myopia	_	_	NN	_	_	_	_	_
45	,	_	_	,	_	_	_	_	_
46	gastric	_	_	JJ	_	_	_	_	_
47	mucosal	_	_	JJ	_	_	_	_	_
48	irritation	_	_	NN	_	_	_	_	_
49	,	_	_	,	_	_	_	_	_
50	sperm	_	_	NN	_	_	_	_	_
51	damage	_	_	NN	_	_	_	_	_
52	,	_	_	,	_	_	_	_	_
53	and	_	_	CC	_	_	_	_	_
54	hematuria	_	_	NN	_	_	_	_	_
55	.	_	_	.	_	_	_	_	_


1	Tinidazole	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	N1-position	_	_	NN	_	_	_	_	_
5	modified	_	_	VBN	_	_	_	_	_
6	5-nitro	_	_	NN	_	_	_	_	_
7	imidazole	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	which	_	_	WDT	_	_	_	_	_
10	has	_	_	VBZ	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	approved	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	FDA	_	_	NNP	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	treatment	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	giardiasis	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Nitazoxanide	_	_	NNP	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	NTZ	_	_	NNP	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	belongs	_	_	VBZ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	an	_	_	DT	_	_	_	_	_
8	emerging	_	_	VBG	_	_	_	_	_
9	class	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	5-nitrothiazole	_	_	NN	_	_	_	_	_
12	compounds	_	_	NNS	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	potential	_	_	JJ	_	_	_	_	_
15	antigiardial	_	_	JJ	_	_	_	_	_
16	activity	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	although	_	_	IN	_	_	_	_	_
4	NTZ	_	_	NNP	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	generally	_	_	RB	_	_	_	_	_
7	well	_	_	RB	_	_	_	_	_
8	tolerated	_	_	VBN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	some	_	_	DT	_	_	_	_	_
11	adverse	_	_	JJ	_	_	_	_	_
12	effects	_	_	NNS	_	_	_	_	_
13	such	_	_	JJ	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	abdominal	_	_	JJ	_	_	_	_	_
16	pain	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	diarrhea	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	nausea	_	_	NN	_	_	_	_	_
22	limit	_	_	VBP	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	safe	_	_	JJ	_	_	_	_	_
25	use	_	_	NN	_	_	_	_	_
26	for	_	_	IN	_	_	_	_	_
27	human	_	_	JJ	_	_	_	_	_
28	beings	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Mepacrine	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	no	_	_	RB	_	_	_	_	_
4	longer	_	_	RBR	_	_	_	_	_
5	available	_	_	JJ	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	United	_	_	NNP	_	_	_	_	_
9	States	_	_	NNPS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	it	_	_	PRP	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	being	_	_	VBG	_	_	_	_	_
15	replaced	_	_	VBN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	most	_	_	JJS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	its	_	_	PRP$	_	_	_	_	_
20	applications	_	_	NNS	_	_	_	_	_
21	with	_	_	IN	_	_	_	_	_
22	safer	_	_	JJR	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	more	_	_	RBR	_	_	_	_	_
25	specific	_	_	JJ	_	_	_	_	_
26	drugs	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Furazolidone	_	_	NNP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	serious	_	_	JJ	_	_	_	_	_
5	side	_	_	NN	_	_	_	_	_
6	effects	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	such	_	_	JJ	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	gastrointestinal	_	_	JJ	_	_	_	_	_
11	disturbances	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	hemolytic	_	_	JJ	_	_	_	_	_
14	anemia	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	disulfiram-like	_	_	JJ	_	_	_	_	_
17	reactions	_	_	NNS	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	alcohol	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	hypersensitivity	_	_	NN	_	_	_	_	_
23	reactions	_	_	NNS	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	as	_	_	RB	_	_	_	_	_
26	well	_	_	RB	_	_	_	_	_
27	as	_	_	IN	_	_	_	_	_
28	evidence	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	tumorigenicity	_	_	NN	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	rodent	_	_	NN	_	_	_	_	_
33	studies	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	G.	_	_	NNP	_	_	_	_	_
4	lamblia	_	_	NNP	_	_	_	_	_
5	resistance	_	_	NN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	this	_	_	DT	_	_	_	_	_
8	drug	_	_	NN	_	_	_	_	_
9	has	_	_	VBZ	_	_	_	_	_
10	also	_	_	RB	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	reported	_	_	VBN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	research	_	_	NN	_	_	_	_	_
4	focusing	_	_	VBG	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	development	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	novel	_	_	JJ	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	alternative	_	_	JJ	_	_	_	_	_
12	drugs	_	_	NNS	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	treatment	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	giardiasis	_	_	NN	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	highly	_	_	RB	_	_	_	_	_
20	desirable	_	_	JJ	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	view	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	these	_	_	DT	_	_	_	_	_
5	considerations	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	researchers	_	_	NNS	_	_	_	_	_
8	have	_	_	VBP	_	_	_	_	_
9	designed	_	_	VBN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	synthesized	_	_	VBN	_	_	_	_	_
12	some	_	_	DT	_	_	_	_	_
13	novel	_	_	JJ	_	_	_	_	_
14	molecules	_	_	NNS	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	treatment	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	giardiasis	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	their	_	_	PRP$	_	_	_	_	_
22	results	_	_	NNS	_	_	_	_	_
23	are	_	_	VBP	_	_	_	_	_
24	summarized	_	_	VBN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	Table	_	_	NNP	_	_	_	_	_
27	1	_	_	CD	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_

